. Tumor shrinkage (n=2, lymphoma), stable disease >3 months (n=5, renal, prostate, oropharynx, cholangiocarcinoma, and Hodgkin lymphoma), and tumor marker reductions (n=1, colorectal cancer/CEA) were
. Pharmacokinetic (PK) sampling was performed during cycles 1 and 2; pharmacodynamic (PD) assessment for microtubule bundle formation (MTBF) was performed after the 1st dose, only at or above 100 mg/m 2 .
Results Thirty-two patients were enrolled, and twenty-nine completed ≥1 cycle of therapy. Dose limiting toxicity [DLT] was observed at 120 mg/m 
Introduction
Agents that target microtubules have potent cytotoxic effects, and are among the most commonly prescribed anti-cancer therapies. The taxanes (paclitaxel and docetaxel) bind and stabilize tubulin, preventing depolymerization of microtubules, resulting in G 2 /M phase arrest and induction of apoptosis [1] [2] [3] . Taxanes have welldocumented activity in several malignancies including breast, ovarian, and lung cancer. Despite this activity, acquired drug resistance is frequently encountered through over-expression of drug efflux protein P-glycoprotein or mutation of β-tubulin [4] [5] [6] . In addition, many tumor types are inherently resistant to taxanes.
The epothilones represent a class of non-taxane drugs capable of stabilizing the tubulin structure by binding to β-tubulin in a manner similar to paclitaxel, causing cell cycle arrest at the G 2 /M transition [7] [8] [9] . Although taxanes and epothilones occupy the same binding site on β-tubulin, electron crystallography and molecular modeling suggest that epothilones do not share a common pharmacophore with taxanes [10] . The epothilones were first discovered in the early 1990's as naturally occurring macrolides [11] . Epothilone A and epothilone B are secondary metabolites isolated from the myxobacterium Sorangium cellulosum. In addition, numerous epothilone analogs have been synthesized. Multiple epothilones have entered clinical trials, including ixabepilone, patupilone, BMS-310705, KOS-1584,ZK-EPO and KOS-862 [12] [13] [14] [15] [16] . Thus far ixabepilone is the only Food and Drug Administration (FDA) approved epothilone. Ixabepilone is approved as monotherapy for the treatment of locally advanced or metastatic breast cancer resistant or refractory to anthracyclines, taxanes, and capecitabine; additionally, it is indicated in combination with capecitabine in patients with locally advanced or metastatic breast cancer that is resistant to anthracyclines and taxanes, or resistant to taxanes with contraindications to anthracycline therapy [14] .
Epothilone D (KOS-862) ( Fig. 1) , is a more potent microtubule stabilizer in vitro than epothilone A or B [17] . In vitro, KOS-862 (Epothilone D) has shown potent cytotoxicity in a panel of human tumor cell lines, with similar potency to paclitaxel. It also showed a definite advantage over paclitaxel in drug-resistant cell lines, and retained its cytotoxicity against a multidrug resistant cell line over-expressing P-glycoprotein [18, 19] . In vivo, antitumor efficacy has been observed in both paclitaxelsensitive and -resistant xenografts, as well as certain multidrug resistant xenografts including a doxorubinresistant CCRF-CEM leukemic cell xenograft [18, 20, 21] .
This phase I study was designed to determine the maximum tolerated dose (MTD), the pharmacokinetics (PK), and the safety profile of KOS-862 administered as a weekly infusion for 3 of 4 (Schedule A) or for 2 of 3 weeks (Schedule B). The study was also designed to measure microtubule bundle formation (MTBF) in Peripheral Blood Mononuclear Cells (PBMCs) of treated patients as a pharmacodynamic (PD) endpoint.
Patients and methods

Patient selection
Eligible patients had an advanced solid tumor or lymphoma with no known curative therapy. Patients also required: measurable or clinically evaluable disease, a Karnofsky Performance Status (KPS)≥60, AST and ALT≤2.5 times the upper limit of normal (≤ 5 times for patients with liver metastases), bilirubin ≤ 2.0 mg/dL (unless Gilbert's disease), serum creatinine≤1.5 mg/dL, absolute neutrophil count≥ 1,500/mL, platelet count ≥ 75,000/mL. and hemoglobin≥8.0 g/dL. Exclusion criteria included: (1) pre-existing peripheral neuropathy (PN)≥grade 2; (2) HIV positive patients; or (3) previous chemotherapy or radiation therapy within 4 weeks of study drug administration. Prior treatment with a taxane was permitted but not required. Memorial SloanKettering's Institutional Review Board approved the study, and written informed consent was obtained from enrolled patients. 2 for Schedule A. This dose was set at one-third the toxic-dose-low in the dog and administered weekly for 3 weeks out of 4. Dose escalation was performed using an NCI-FDA accelerated design scheme [18] . Doses were doubled in successive 3-person cohorts until either 1 instance of DLT or 2 instances of drug-related grade 2 toxicity (except for nausea/vomiting, fatigue, anorexia, alopecia, or anemia) were observed, at which time 3 additional patients were added to the cohort. Thereafter, the dose escalation followed a modified Fibonacci sequence (i.e., dose increments of 67%, 50%, 40%, 33%, and 25%). A second schedule (Schedule B) tested drug administration every 2 weeks out of 3 (day 1 and 8 of a 21 day cycle). Schedule B dose level was fixed at the MTD observed in Schedule A (100 mg/m 2 ). Both schedules used a fixed time of administration (90 min) for all doses. No intra-patient dose escalation was allowed.
The DLT was defined as either: (1)≥grade 3 nonhematologic toxicities except fever, chills, or flu-like symptoms; (2)≥grade 3 thrombocytopenia; (3) grade 4 neutropenia >5 days; (4) febrile neutropenia during cycle 1 of therapy; or (5) re-treatment delay >3 weeks.
When at least 2 of 6 patients in any given dose cohort experienced a DLT, there was to be no further dose escalation and this dose level was called the maximum administrable dose (MAD). The dose level immediately below the MAD was identified as the maximum tolerated dose (MTD). Additional patients (up to 10) were then enrolled at the MTD to gain additional information regarding the toxicity profile and PK parameters.
Prior to study drug infusion, the first 6 patients were premedicated with antihistamines per Regimen A (loratadine 10 mg PO and famotidine 20 mg PO or equivalently dosed substitute) given at least 30 min prior to treatment. The remainder of patients were premedicated with antihistamines and low-dose steroids per Regimen B (H 1 and H 2 blockers as above and either methylprednisolone 40 mg IV or dexamethasone 10 mg IV) at least 30 min prior to treatment.
The primary objective of the study was to determine MTD and DLT for each of the 2 schedules. Secondary objectives were to define safety and plasma PK profile, and to assess PD sampling and potential antitumor activity.
Treatment assessment
Baseline assessment included a physical examination, review of systems, complete blood count (CBC) with differential, hepatic and renal function tests, coagulation parameters, urinalysis, 12-lead electrocardiogram (ECG), and chest x-ray. Negative pregnancy test was required for women of childbearing potential. Tumor measurements with CT scan or MRI were performed at baseline. During the study, history, physical examination, weight, vital signs, KPS, CBC, and blood chemistries were monitored weekly. Urinalysis was evaluated every 3 weeks. Additional safety monitoring included neurological evaluation by physical examination following infusions, and ECG pre-and postinfusion. Radiographic tumor response assessment was performed at least every 2 cycles (every 6-8 weeks), with response assessed according to the WHO RESICT criteria. 
Analytical method
Plasma concentrations of KOS-862 were measured using a validated, automated HPLC/MS method. In brief, patient plasma samples, quality control samples, and calibrators were thawed in an ice bath and then vortex mixed. Aliquots (100 μL) of samples were pipetted into 1.2 mL titer tubes, 800 μL internal standard (IS, Epothilone C, concentration 25 ng/mL in acetonitrile) was added, and the samples were then transferred to an auto tube holding plate according to a generated sequence.
Extraction was performed with the TOMTEC Quadra 96 TM using a solid phase extraction method. Prior to loading samples, the SPE cartridges (Versaplate, C18, 50 mg) were conditioned with 600 μL methanol and with 700 μL of 1.0% trifluoroacetic acid (TFA) in water. After loading the samples, cartridges were washed with 2,100 μL water and then 1,050 μL 10/90 (v/v) methanol/water. Samples were eluted with 600 μL methanol and the eluent evaporated to dryness at 60°C with nitrogen in a Zymark Turbovap 96.
Samples were reconstituted in 400 μL of 50:50 (v/v) methanol/water, vortex mixed and transferred to injection vials. Samples were injected into a Perkin Elmer Series 200 with a Keystone Hypersil C18 column (30×4.6, 3.0 μm). Mobile phase was methanol:1.0% formic acid in water (70:30, v/v).
A Perkin Elmer Sciex API 3000 with turbo ion spray source was used to analyze the effluent from the chromatographic column. The analytes were detected using selected reaction monitoring in positive ion mode. Fragmentation of the precursor ions was achieved using nitrogen as collision gas and collision energy (E lab ) of 35 eV for KOS-862 and Epothilone C. The mass transitions monitored were m/z 492→304 for KOS-862 and 478→290 for Epothilone C, respectively. Analyte quantitation was done by peak area ratio using a linear equation weighted 1/Y.
The intra-assay and inter-assay precision (average %CV) at the lower limit of quantitation was 3.6% and 8.9%, respectively.
Results
Patient characteristics and treatment administration
Thirty-two patients were registered to the study, with 29 patients receiving at least one dose of study drug. Demographics and disease characteristics of patients treated on Schedules A and B are listed on Table 1 . The median age of patients was 55 years (range, 25-77), the male-tofemale ratio was 15:17, and the median KPS was 80% (range, 70-100). The median number of prior chemotherapeutic, hormonal, or immune regimens was 5 (range, 2-9).
For Schedule A, cohorts of three to six patients were treated at each dose level until the MTD was defined. Once the MTD was identified, this dose level was expanded to 10 patients to better define the tolerability and pharmacokinetics of the dose. Schedule B was started at the MTD defined by Schedule A.
Of the 32 patients enrolled in the trial, 22 received Schedule A (intravenous dose administered every 3 weeks out of 4 over 90 min) and 10 patients received Schedule B (intravenous dosing every week 2/3 via the same constant time infusion). Doses ranged during Schedule A from 16-120 mg/m 2 ; all patients received 100 mg/m 2 on Schedule B. All 22 patients who entered Schedule A completed the first study period, Cycle 1 Day 1; eighteen patients completed both study periods in Cycle 1; 15 patients continued to complete Cycle 2 Day 1. All patients were included in the data analysis.
During the conduct of the Protocol, several patients were dose reduced from the initial dose level to one dose level lower. Two patients initially at dose level 100 mg/m 2 were de-escalated to 75 mg/m 2 in Cycle 3 (PK sampling was not affected); one patient initially treated at 120 mg/m 2 was deescalated to 100 mg/m 2 ; this affected PK sampling on Cycle 2/Day 1. For the pharmacokinetic analysis this patient was included in a cohort based on the actual dose administered rather than in the original cohort to which she was accrued Overall, the median number of cycles administered was 2 (range, 1-6). Twenty-six of 32 patients (81%) came off of study due to progression of disease; 3 patients (9%) were removed from the study due to DLT events. A summary of the dose escalation and dosing schedule for each cohort of patients is provided in Table 2 .
Pharmacokinetics
Compartment-independent PK analysis demonstrated no evidence of nonlinear PK at the doses and administration schedules studied, although the data suggested a tendency toward nonlinearity of systemic exposure and maximal plasma concentration at the highest dose administered. KOS-862 plasma concentration curves showed a rapid distribution phase followed by a slower elimination phase with no appreciable change of slope as the dose increased ( Fig. 2a and b) . The plasma concentration curve measured at repeated dosing at weekly intervals (Schedule A) also demonstrated a stationary PK with negligible changes (Fig. 4) , and appeared to demonstrate some deviation from linearity at 120 mg/m 2 on Schedule A. For the dose of 100 mg/m 2 , the maximal plasma concentration peaked at the end of the infusion in the majority of patients, at 3,688±1,053 ng/mL for Schedule A and 4,825±1,360 ng/mL for Schedule B.
Intra-patient variability (based on a comparison of the PK of individual patients given doses 7 days apart) was negligible. Inter-patient variation within cohorts was sometimes significant, in several cases with 3-fold variation between patients in systemic exposure. Gender differences in this protocol were confined to the V ss and apparent volume of distribution during the terminal half-life (V z ) when uncorrected for BSA. Females showed significantly smaller V ss than males (111.51±48.04 vs. 159.28±73.67 L, respectively), and lower apparent volume of distribution during the terminal half-life (V z ) (182.98±83.10 vs. 240.87± 108.73 L, respectively). The difference disappeared when the V z and V ss were corrected for BSA. No gender differences were seen for AUC tot , t ½ , or clearance. ; PK is dose independent N=14 patients on Schedules A and B (mean+SD) Pharmacodynamics KOS-862 induced MTBF in PBMCs in a dose-and timedependent manner that failed to correlate with AUC tot , C max , t ½ , and clearance. Although it is not possible to actually measure the concentration of drug in the effect compartment, the PK/PD modeling indicated that KOS-862 at 900 to 1,900 ng/mL in the tumor would result in MTBF in greater than 35% of the cells.
DLT and MTD
There was one DLT in 1 of 10 patients at 100 mg/m 2 in Schedule A (grade 2 peripheral sensory neuropathy), and 2 of 10 patients at 100 mg/m 2 in Schedule B (grade 2 peripheral sensory neuropathy and visual hallucination). None was experienced by more than one patient, and only one patient required a dose reduction to 75 mg/m 2 . Two cases of peripheral sensory neuropathy occurred after 2 nd infusion, and resolved within 7-8 days. Visual hallucination occurred in one patient after Cycle 1, infusion 1 in Schedule B; the dose was reduced to 75 mg/m 2 for subsequent cycles with no recurrence of DLT.
At 120 mg/m 2 , 3 DLTs occurred in 2 of 2 patients in Schedule A. One patient had a transient visual hallucination (<1 min) requiring no action on study medication; a second patient had severe NVD with dehydration. This patient was dose reduced to 100 mg/m 2 and re-challenged without recurrence of this toxicity. Based on these DLTs, 100 mg/m 2 on Schedule A was considered the MTD and the recommended dose for Phase II studies.
Possible hypersensitivity reactions (HSR) were observed in 5 patients. Initially, patients received premedication Regimen A (antihistamines only), and 2 of 6 (33%) experienced a possible HSR. Subsequently, all patients were converted to Regimen B (antihistamines with lowdose steroids) and the incidence of these reactions occurred in 3 of 26 (12%).
Other toxicities
All patients in the study had at least one adverse event (AE). In Schedule A, the most frequent treatment-related AEs included fatigue (59%), peripheral sensory neuropathy (41%), diarrhea (36%), and constipation (32%). Treatmentrelated AEs that were somewhat more frequent in the higher dose groups included diarrhea, nausea, skin and subcutaneous tissue disorders, peripheral sensory neuropathy, insomnia, and exertional dyspnea. In Schedule B, the most frequently reported treatment-related AEs were fatigue (70%), peripheral sensory neuropathy (50%), insomnia (50%), and anemia (40%).
Six of 18 evaluable patients (33%) in Schedule A and 5 of 9 evaluable patients (55%) in Schedule B experienced a decrease in their KPS, that was possibly treatment related. Six of 22 patients (27%) in Schedule A experienced weight loss >5% from baseline (6.8-15%), most (4 out of 6 patients) occurring at 100 mg/m 2 . Two of 10 (20%) patients in Schedule B experienced weight loss of >5% from baseline (9.3-11.8%) during the first 2 weeks of starting therapy.
In Schedule A, 8 patients (38%) among 22 experienced serious adverse events (SAEs), including 2 deaths; both occurred during the 30-day follow-up period and neither was considered related to the study drug. The causes of death were respiratory failure and failure to thrive. Of the 18 SAEs experienced by these 8 patients, 11 (61%) were considered not related to study drug; 3 (17%) were considered unlikely related to study drug, including pain in limb, muscle weakness, and ventricular arrhythmia; and 4 (22%) were considered possibly or probably related to study medication, including dehydration, diarrhea, and . This graph demonstrates a stationary PK with negligible changes upon repeated dosing at weekly intervals syncope, all experienced by the same patient. Four patients were removed from the study because of AEs, including diarrhea, nausea, hypotrichosis, peripheral sensory neuropathy, syncope, and ventricular arrhythmia.
In Schedule B, there were no deaths among the 10 patients treated or during the 30-day follow-up period. Five patients (50%) experienced a total of 7 SAEs, including anemia, small bowel obstruction, cellulitis, dehydration, failure to thrive, and hemoptysis. With the exception of anemia, no SAEs occurred in more than one patient. Of the 7 SAEs, 5 (71%) were considered not related to study drug; one (14%), small-bowel obstruction, was considered unlikely related; and one (14%), anemia, was considered possibly related. Two patients (20%) were discontinued because of AEs, which were hemoptysis, anemia, anorexia, dehydration, failure to thrive, and vomiting. Toxicities (≥ grade 3) related to study drug are listed in Table 3 .
With both schedules of administration, marginal decreases in white blood cell count, absolute neutrophil count, and hemoglobin were observed during treatment. No clinically significant effects on platelet counts, total bilirubin, or AST were observed.
Increases in systolic blood pressure≥25 mmHg during infusions were observed in 22% of patients. These increases were transient and probably reflected hypersensitivity to the Cremophor® in the drug formulation.
ECGs were performed on 17 patients prior to each infusion and at 1 h after completion, in addition to those performed at baseline and termination. QT c prolongation (> 450 msec at 1-hour post-dose of >60 msec increases from pre-dose to 1 h post-dose) was observed in 10 of these 17 patients (58%). All of these episodes returned to a normal range by the subsequent infusion. None of the patients developed QT c >500 msec, and there was no associated occurrence of malignant arrhythmia or sudden death.
Neurological examinations revealed treatment-emergent sensory neuropathy (hands/ft) to be the most frequent neurotoxicity, and it was dose limiting (grade 2) in 2 patients at 100 mg/m 2 . In Schedule A, treatment-emergent peripheral neuropathy (PN) was reported in 36% of patients, 41% of whom experienced numbness and tingling.
These findings were more frequent among the patients treated at 100 mg/m 2 (60% PN). In Schedule B, 80% of patients had treatment-emergent PN, which consisted mostly of numbness (50%) and tingling (80%). Pain, burning, and motor findings were less frequent in both schedules.
Non-sensory neurotoxicity ranged in severity, and was clearly dose-dependent. While patients at lower doses experienced weakness upon standing, those at higher doses (≥100 mg/m 2 ) developed frank ataxia. Similarly, while cognitive/perceptual abnormalities (confusion, dizziness, blurry vision) occurred at lower doses, visual hallucinations were seen at higher doses. Neurotoxicity typically reached maximum severity 1-3 days following infusion, with resolution over the ensuing 1-5 days.
Antitumor activity
No patient in Schedule A or Schedule B experienced a response by WHO-RECIST criteria. Tumor shrinkage was observed in two patients with diffuse large B-cell (27% decrease in target lesions after Cycle 2 at 100 mg/m 2 in Schedule A) and Hodgkin lymphoma (18% decrease in target lesions and a CR of non-target lesions after Cycle 3 at 100 mg/m 2 in Schedule B). In addition, SD≥3 months was seen in patients with renal (n=1, papillary subtype), prostate (n=1), oropharynx cancer (n=1), cholangiocarcinoma (n=1), and Hodgkin lymphoma (n=1). All of these outcomes were observed in the 100 mg/m 2 group. One patient with colorectal cancer experienced a 37% decrease in tumor marker level (CEA) after 3 cycles of therapy. This patient was considered to have had progressive disease at study termination by radiographic criteria, although the patient's condition remained clinically stable 2 months following discontinuation of therapy.
Discussion
In this report, we present the results of the initial phase I dose-escalation study of the epothilone KOS-862 (Epothi- lone D) in patients with advanced solid tumors or lymphoma. As with other epothilones, the most prominent toxicities appeared to be neurologic and gastrointestinal. The primary DLT was a reversible neurotoxicity, which was dose related. Although a limited number of patients received more than 2 cycles, the toxicities were not cumulative. The DLT of KOS-862 appears to be scheduleindependent. Other phase I evaluations have also identified neurotoxicity as dose-limiting [22, 23] .
Transient, mild QT c prolongation (>450 msec but <500 msec) was observed in 10 of the 17 patients (58%) when measured pre-and 1 h post-infusion. All of these episodes were isolated events with no accompanying symptoms, and the QT c intervals returned to a normal range by the next dose. No ECG abnormality was associated with any occurrence of malignant arrhythmia or sudden death. However, for future studies, a routine monitoring of ECGs is recommended, and persistent QT c elevation >500 msec or associated symptoms should warrant further evaluation.
Based on the toxicity profile at the MTD, the recommended phase II dose is 100 mg/m 2 weekly 3 weeks out of every 4. Toxicities at this dose level that were not dose-limiting included: fatigue (50%), reversible peripheral neuropathy (hypoesthesia 40%; paresthesia 30%), dizziness (30%), nausea/vomiting/diarrhea (30%) not requiring prophylaxis, and anemia (mild). This dose and schedule carries an overall weekly dose intensity of 75 mg/m [23] ; 4 mg/h×24 h every 2 weeks (48 mg/week) [22] ; and 1 mg/h×72 h every 2 weeks (36 mg/week) [22] . Weekly, non-protracted dosing used in this study appears preferable since it is better tolerated, easy to administer, and achieves higher systemic exposures.
Although preclinical data demonstrating that a 6-hour infusion (V ss~5 00 ng/mL) in the mouse xenograft model demonstrated optimal antitumor efficacy [18] , phase I trials investigating continuous infusion schedules (24-hour and 72-hour continuous infusion every 2 weeks) did not result in greater antitumor effect [22] . The weekly study schedule of 3 weeks out of 4 weeks from this clinical trial, therefore, was advanced into phase II clinical trials.
In this study, KOS-862 demonstrated modest signs of antitumor activity. While no formal PR or CR was achieved by WHO-RECIST criteria, tumor shrinkage was observed in 2 patients with diffuse large B-cell and Hodgkin lymphoma. In addition, SD (≥ 3 months) was seen in renal, prostate, andoropharyngeal cancer, cholangiocarcinoma, and Hodgkin lymphoma. In addition, a 37% decline in CEA was observed in a patient with colorectal cancer.
KOS-862 displayed linear kinetics over all studied doses. The drug achieved a t ½ approximating 10 h.
Microtubule bundle formation in PBMCs is a marker of the ability of a microtubule-stabilizing drug to bind to its target in vivo and induce tubulin polymerization, however data is lacking as to whether MTBF can be directly correlated with anti-tumor activity [24] . MTBF was found to be both a time-and dose-dependent PD endpoint, though no correlation with AUC tot was found. Bundle formation was observed at all post-infusion time points. PK/PD analysis supports 1,000 ng/mL as the target intratumoral drug concentration for optimal biological effect (using % microtubule bundling) in humans.
In conclusion, KOS-862 was generally well tolerated in this patient population with a favorable PK profile and the suggestion of clinical activity in patients with lymphoma. KOS-1584 is a synthetic analogue of KOS-862. This second generation epothilone was designed to have a longer half-life, larger volume of distribution, less toxicity, more potency and higher solubility than KOS-862 [25] . The first-in-human study of KOS-1584 showed a favorable toxicity profile and early evidence of activity [25] . Further development of KOS-862 was therefore halted at the phase II level in favor of additional development of KOS-1584. The lessons learned from this phase I study of KOS-862 presented here were vital to our understanding of the toxicities associated with epothilones and have led to further development and refinement of this class of drugs.
Recently, epothilone B (Ixabepilone) was approved by the FDA for treatment of metastatic breast cancer, and the clinical niche to be filled by epothilones will likely expand. There are now multiple phase II trials completed with various epothilone analogs in cancers in which taxanes are known to be effective (breast [26] [27] [28] , endometrial [28] , ovarian [29] , lung [30] , head & neck [31] , prostate [32, 33] , germ cell tumor [34] , pancreas [35] , gastric adenocarcinoma [36] ). There are also completed phase II trials with various epothilone analogs in cancer in which taxanes are not known to be effective (colorectal [37] , renal cell [31, 38] , NHL [39] ). In addition, there are completed and in-progress clinical trials examining epothilones in combination with capecitabine, estramustine, gemcitabine, carboplatin, trastuzumab, liposomal doxorubicin, irinotecan, and mitoxantrone [40] [41] [42] [43] [44] [45] .
